A Randomized, Open-label, Parallel-group, Single Subcutaneous Dose, Relative Bioavailability Study of the Pharmacokinetics of Lulizumab (BMS-931699) From Prefilled Syringe (Process A) Compared to Drug in Vial (Process A) in Healthy Participants
Latest Information Update: 16 Jan 2020
Price :
$35 *
At a glance
- Drugs Lulizumab pegol (Primary)
- Indications Sjogren's syndrome; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 18 Dec 2017 Status changed from not yet recruiting to discontinued.
- 02 Mar 2017 New trial record